21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
15:12 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

AIT reports Phase II data for lung infection candidate

AIT Therapeutics Inc. (Pink:AITB) reported data from nine patients with non-tuberculosis Mycobacterial (NTM) infections in the Phase II NO-NTM Abscessus trial showing that AIT-NTM for 21 days led to a mean reduction in...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...